---
title: "ChengDu Sheng Nuo Biotec Co.,Ltd. (688117.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688117.SH.md"
symbol: "688117.SH"
name: "ChengDu Sheng Nuo Biotec Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-21T16:08:23.187Z"
locales:
  - [en](https://longbridge.com/en/quote/688117.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688117.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688117.SH.md)
---

# ChengDu Sheng Nuo Biotec Co.,Ltd. (688117.SH)

## Company Overview

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. ChengDu ShengNuo Biotec Co.,Ltd.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.snbiopharm.com](https://www.snbiopharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:14.000Z

**Overall: B (0.31)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 45 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 49.42% |  |
| Net Profit YoY | 119.62% |  |
| P/B Ratio | 4.95 |  |
| Dividend Ratio | 0.37% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5560753041.63 |  |
| Revenue | 799863169.66 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 16.95% | A |
| Profit Margin | 22.11% | A |
| Gross Margin | 59.87% | A |
| Revenue YoY | 49.42% | A |
| Net Profit YoY | 119.62% | A |
| Total Assets YoY | 20.64% | A |
| Net Assets YoY | 16.40% | B |
| Cash Flow Margin | 83.29% | C |
| OCF YoY | 49.42% | A |
| Turnover | 0.44 | C |
| Gearing Ratio | 44.00% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - ChengDu Sheng Nuo Biotec Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "49.42%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "119.62%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.95",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.37%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5560753041.63",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "799863169.66",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "16.95%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "22.11%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "59.87%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "49.42%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "119.62%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "20.64%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "16.40%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "83.29%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "49.42%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.44",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "44.00%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 31.03 | 73/215 | 58.94 | 52.32 | 49.02 |
| PB | 4.89 | 185/215 | 6.46 | 5.99 | 5.54 |
| PS (TTM) | 6.86 | 156/215 | 10.83 | 9.81 | 8.99 |
| Dividend Yield | 0.38% | 139/215 | 0.36% | 0.33% | 0.25% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-25T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 34.93 |
| Highest Target | 46.00 |
| Lowest Target | 46.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688117.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688117.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688117.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**